You are viewing: UK Theranostics Market analysis
Part of: Theranostics Market (Global)

The UK Theranostics Market was valued at $113 Million in 2023 and projected to reach to $170.7 Million by 2028, representing a compound annual growth rate of 8.6%. The UK theranostics market is positioned for sustained growth driven by increasing NHS investment in precision medicine and molecular diagnostics.

UK Theranostics Market (2023-2028) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UK Theranostics Market Trends and Insights

  • The UK's advanced healthcare infrastructure and strong regulatory framework position it as a key market for theranostic innovations, which combine diagnostic and therapeutic capabilities in a single agent.
  • The UK's investment in precision medicine and personalized treatment approaches is driving adoption of theranostic solutions across oncology, cardiology, and neurology applications. The UK theranostics market benefits from robust NHS funding, increasing collaboration between academic institutions and pharmaceutical companies, and growing patient demand for targeted therapies.
  • Between 2023 and 2028, the UK is expected to see accelerated development of novel theranostic agents, particularly in nuclear medicine and molecular imaging.
  • The UK's regulatory environment, supported by the MHRA and EMA frameworks, facilitates faster clinical translation of theranostic technologies compared to many global markets..

Key Market Statistics

  • CAGR (2023-2028) 8.6% CAGR
  • Market Size, 2023 ~USD 113 Million
  • Forecast, 2028 ~USD 170.7 Million
  • Country UK

UK Theranostics Market Overview

Market Valuation :

The UK theranostics market was valued at £113.0 million in 2023 and is projected to reach £170.7 million by 2028, demonstrating steady growth in this innovative healthcare segment.

Regulatory Leadership :

The UK's robust regulatory framework through the MHRA and NHS approval pathways provides a competitive advantage for theranostic product development and commercialisation compared to other European markets.

Healthcare Infrastructure :

Advanced NHS facilities and research institutions across the UK support the adoption of theranostic technologies, with particular strength in oncology and molecular imaging centres.

Growth Trajectory :

At 8.6% CAGR, the UK market is growing steadily, though below the global average of 15.5%, indicating untapped potential for market expansion and innovation acceleration.

UK Theranostics Market Dynamics

  • The integration of diagnostic and therapeutic capabilities aligns with the UK's commitment to personalised healthcare delivery, particularly in oncology and rare disease management.
  • Healthcare providers are increasingly adopting theranostic approaches to improve patient outcomes and reduce treatment costs. Future expansion will be supported by growing collaboration between academic institutions, pharmaceutical companies, and NHS trusts.
  • Regulatory streamlining post-Brexit and increased R&D funding for life sciences create favourable conditions for theranostic innovation.
  • However, reimbursement challenges and the need for robust clinical evidence remain key considerations for market penetration and sustained growth through 2028..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • SANOFI
  • Merck KGaA
  • NOVARTIS
  • Pfizer Inc.

    Key Takeaways

    • The UK theranostics market is valued at £113.0 million in 2023 and will reach £170.7 million by 2028 at 8.6% CAGR.
    • The UK's precision medicine initiatives and NHS support are key drivers of theranostic adoption across multiple therapeutic areas.
    • The UK regulatory framework enables faster clinical translation of theranostic innovations compared to global benchmarks.
    • The UK market is characterized by strong academic-industry partnerships and increasing investment in nuclear medicine and molecular imaging technologies.

    Theranostics Market Report Scope

    Report Metric Details
    Base Year 2023
    Fastest Growing Segment THERANOSTICS CENTERS (End User)
    Forecast Period 2023-2028
    Growth Rate CAGR of 15.5% from 2023 to 2028
    Largest Segment RADIOPHARMACEUTICALS (Product)
    Market Size Base Year (Billions) ~USD 2.09 (2023)
    Revenue Forecast (Billions) ~USD 4.3 (2028)
    Segments Covered Product, Type, Application, End User

    UK Theranostics Market Report Segmentation

    4 segment dimensions are covered across the global market.

    By Product

    • Diagnostic Imaging
    • Ivd/Biomarker Screening
    • Radiopharmaceuticals
    • Software & Services

    By Type

    • Iodine-131
    • Lutetium-177
    • Other Radiopharmaceuticals
    • Radium-223
    • Samarium-153
    • Yttrium-90

    By Application

    • Bone Metastasis
    • Other Applications
    • Other Cancer
    • Other Cancers
    • Prostate Cancer

    By End User

    • Hospitals And Cancer Care Centers
    • Research And Academic Centers
    • Theranostics Centers

    Target Audience

    • Pharmaceutical & Biotech Companies : UK and international firms developing theranostic products need market-specific data to guide R&D investments, regulatory strategies, and commercialisation plans for the British market.
    • Healthcare Investors & PE Firms : Investment professionals evaluating UK healthcare opportunities require detailed market sizing and growth projections to assess theranostics as an emerging investment thesis.
    • NHS Trusts & Hospital Networks : Healthcare providers and procurement teams need market intelligence to evaluate theranostic adoption, budget allocation, and integration into diagnostic and treatment pathways.
    • Medical Device & Diagnostics Manufacturers : Companies in imaging and diagnostic sectors require UK market data to identify theranostics as a growth opportunity and develop complementary product portfolios.
    • Policy Makers & Health Authorities : UK government agencies and health policy organisations need market insights to inform precision medicine strategies, funding decisions, and regulatory framework development.

    Reasons to Buy this Report

    • UK-Specific Market Sizing : Obtain precise valuation data for the UK theranostics market with detailed 2023-2028 forecasts, enabling accurate business planning and investment decisions tailored to the British healthcare landscape.
    • Regulatory & Reimbursement Insights : Understand MHRA approval pathways, NHS reimbursement mechanisms, and UK-specific regulatory requirements that directly impact product commercialisation timelines and market access strategies.
    • Competitive Landscape Analysis : Identify key UK-based and international players operating in the theranostics space, their market positioning, and strategic initiatives specific to the British healthcare system.
    • Growth Driver Identification : Discover UK-specific factors driving market growth, including NHS funding priorities, clinical adoption rates, and emerging therapeutic areas with highest commercial potential.
    • Strategic Investment Guidance : Make informed decisions on market entry, partnership opportunities, and resource allocation with comprehensive UK market intelligence and forward-looking trend analysis.

    Frequently asked questions

    What is the current size of the UK theranostics market?

    The UK theranostics market was valued at £113.0 million in 2023 and is expected to grow to £170.7 million by 2028.

    What is the growth rate of the UK theranostics market?

    The UK theranostics market is projected to grow at a compound annual growth rate (CAGR) of 8.6% from 2023 to 2028.

    What are the main drivers of growth in the UK theranostics market?

    Key drivers include the UK's investment in precision medicine, NHS funding support, academic-industry collaborations, and increasing demand for targeted therapies in oncology and other therapeutic areas.

    Which therapeutic areas are leading the UK theranostics market?

    Oncology is the primary therapeutic area, with growing applications in cardiology and neurology as theranostic technologies advance in the UK market.

    How does the UK regulatory environment support theranostics development?

    The UK's MHRA and EMA regulatory frameworks facilitate faster clinical translation of theranostic innovations, enabling quicker market entry compared to many other regions.

    RESEARCH METHODOLOGY

    The study involved four major activities in estimating the current size of the theranostics market. Exhaustive secondary research was done to collect information on the market, peer, and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.

    Secondary Research

    The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial theranostics market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various supply and demand sources were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as OEMs, CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the theranostics market. The primary sources from the demand side include medical CDMOs, oncologists, doctors, radiologists, technicians, and service providers. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on key industry trends & key market dynamics.

    A breakdown of the primary respondents is provided below:

    Theranostics Market Size, and Share

    *Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    Note: Companies are classified into tiers based on their total revenue. As of 2021, Tier 1 = >USD 1,000 million, Tier 2 = USD 500–1,000 million, and Tier 3 = <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Estimation Methodology

    In this report, the theranostics market’s size was determined using the revenue share analysis of leading players. For this purpose, key players in the market were identified, and their revenues from the market business were determined through various insigh ts gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as CEOs, directors, and key marketing executives.

    Segmental revenues were calculated based on the revenue mapping of major solution/service providers to calculate the global market value. This process involved the following steps:

    • Generating a list of major global players operating in the theranostics market.
    • Mapping annual revenues generated by major global players from the product segment (or nearest reported business unit/category)
    • Revenue mapping of major players to cover a major share of the global market share, as of 2022
    • Extrapolating the global value of the theranostics market industry

    Theranostics Market Size, and Share

    Data Triangulation

    After arriving at the overall market size from the market size estimation process explained above, the global theranostics market was split into segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the market was validated using top-down and bottom-up approaches.

    Market Definition

    Theranostics is a term used for diagnosis and therapy. Theranostics can be broadly defined as a combination of molecularly targeted imaging and therapy, whereas imaging helps to gain information regarding presence of targeted moleculaes on cell surface and therapy progression. Radiotheranostics involves the use of radionuclide/radiopharmaceutical that delivers targeted radiation to kill the cancerous cells and imaging modality such as positron emission tomography (PET) is used to locate the cancer.  FDA approved theranostics procedures are performed for different applications such as prostate cancer, neuroendocrine tumor, etc. These procedures are mainly performed in hospitals, cancer care centers, and  theranostics centers.

    Key Stakeholders

    • Senior Management
    • End Users
    • R&D Department
    • Finance/Procurement Department

    Objectives of the Study

    • To define, describe, and forecast the size of theranostics market based on product, application, end user, and region
    • To provide detailed information regarding the major factors influencing the growth potential of the global market (drivers, restraints, opportunities, challenges, and trends)  
    • To analyze the micro markets with respect to individual growth trends, prospects, and contributions to the global market.   
    • To analyze key growth opportunities in the global market for key stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of market segments and/or subsegments with respect to three major regions, namely, North America (US and Canada), Europe (Germany, France, the UK, and the RoE), Asia Pacific (Japan, China, India, and the RoAPAC), and Rest of the World (Latin America and Middle East and Africa).
    • To profile the key players in the market and comprehensively analyze their market shares and core competencies.
    • To track and analyze the competitive developments undertaken in the global market, such as product launches; agreements; expansions; and mergers & acquisitions.

    Available Customizations

    With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for the present global theranostics market report:

    Product Analysis

    • Product matrix, which gives a detailed comparison of the product portfolios of the top fifteen companies

    Company Information

    • Detailed analysis and profiling of additional market players (up to five)

    Geographic Analysis

    • Further breakdown of the Rest of Europe theranostics market into Italy, Spain Russia, Belgium, the Netherlands, Switzerland, Austria, Finland, Sweden, Poland, and Portugal, among others
    • Further breakdown of the Rest of Asia Pacific theranostics market into Australia, South Korea, Singapore, Taiwan, New Zealand, Philippines, Malaysia, and other APAC countries

    Get the Full Theranostics Market Report

    Full forecast, segment splits, and company analysis for all Theranostics Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status